For a patient with osteogenic sarcoma, which route is commonly used to administer chemotherapy?

For a patient with osteogenic sarcoma, which route is commonly used to administer chemotherapy?

• A. Intravenous
• B. Intraarterial
• C. Intrathecal
• D. Oral

Answer: (B)

The main idea is to deliver chemotherapy directly to the tumor’s blood supply to achieve very high local drug concentrations. For osteogenic sarcoma, especially in the limbs, infusing the drug through the artery that feeds the tumor concentrates the chemo right at the tumor site. This local boost can shrink the tumor more effectively and help make limb-sparing surgery possible, while still allowing systemic therapy to address micrometastases. While intravenous chemotherapy is also used to treat osteosarcoma systemically, intraarterial administration is commonly chosen in selected cases to maximize the tumor’s exposure to the drug. The other routes don’t provide the same targeted, high local concentrations: intrathecal targets the central nervous system and isn’t suitable for bone tumors, oral administration is limited in achieving the high, controlled doses needed for the tumor, and intravenous delivery spreads the drug more diffusely rather than focusing it on the tumor bed.

The main idea is to deliver chemotherapy directly to the tumor’s blood supply to achieve very high local drug concentrations. For osteogenic sarcoma, especially in the limbs, infusing the drug through the artery that feeds the tumor concentrates the chemo right at the tumor site. This local boost can shrink the tumor more effectively and help make limb-sparing surgery possible, while still allowing systemic therapy to address micrometastases.

While intravenous chemotherapy is also used to treat osteosarcoma systemically, intraarterial administration is commonly chosen in selected cases to maximize the tumor’s exposure to the drug. The other routes don’t provide the same targeted, high local concentrations: intrathecal targets the central nervous system and isn’t suitable for bone tumors, oral administration is limited in achieving the high, controlled doses needed for the tumor, and intravenous delivery spreads the drug more diffusely rather than focusing it on the tumor bed.